Hyperinsulinemia - Pipeline Review, H1 2020
Hyperinsulinemia - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H1 2020, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.
Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H1 2020, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.
Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hyperinsulinemia - Overview
Hyperinsulinemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperinsulinemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperinsulinemia - Companies Involved in Therapeutics Development
AmideBio LLC
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
PegBio Co Ltd
Rezolute Inc
Seneb BioSciences Inc
Sosei Heptares
XERIS Pharmaceuticals Inc
Zealand Pharma AS
Hyperinsulinemia - Drug Profiles
ABG-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avexitide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-02481 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNB-2401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperinsulinemia - Dormant Projects
Hyperinsulinemia - Product Development Milestones
Featured News & Press Releases
Jun 10, 2020: rezolute receives Rare Pediatric Disease Designation for RZ358 phase 2b candidate for the treatment of congenital hyperinsulinism enabling eligibility for priority review voucher
Jun 01, 2020: Rezolute presents RZ358 clinical data-validated model of the pharmacokinetics and glycemic response in congenital hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
May 28, 2020: Rezolute to present clinical data for RZ358, lead candidate in phase 2b trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
Apr 23, 2020: U.S. FDA grants orphan drug designation to AmideBio's glucagon analog for the treatment of congenital hyperinsulinism
Feb 10, 2020: Rezolute initiates Phase 2b clinical trial of lead candidate RZ358 in congenital hyperinsulinism
Jul 29, 2019: Crinetics Pharmaceuticals to receive final award of SBIR grant from NIH for congenital hyperinsulinism
Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on its drug candidate ACTH Antagonist CRN-02481 at ENDO2019
Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism
Apr 09, 2018: Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
Mar 12, 2018: Crinetics Pharmaceuticals Announces Presentation on Hyperinsulinemia Drug Candidate at ENDO 2018
Feb 08, 2018: FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH)
Feb 05, 2018: Hanmi annouces FDA orphan drug designation for LAPSGlucagon Analog
Sep 06, 2017: Crinetics Pharmaceuticals awarded SBIR Grant to develop new therapeutics for congenital hyperinsulinism
Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hyperinsulinemia - Overview
Hyperinsulinemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperinsulinemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperinsulinemia - Companies Involved in Therapeutics Development
AmideBio LLC
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
PegBio Co Ltd
Rezolute Inc
Seneb BioSciences Inc
Sosei Heptares
XERIS Pharmaceuticals Inc
Zealand Pharma AS
Hyperinsulinemia - Drug Profiles
ABG-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avexitide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-02481 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNB-2401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperinsulinemia - Dormant Projects
Hyperinsulinemia - Product Development Milestones
Featured News & Press Releases
Jun 10, 2020: rezolute receives Rare Pediatric Disease Designation for RZ358 phase 2b candidate for the treatment of congenital hyperinsulinism enabling eligibility for priority review voucher
Jun 01, 2020: Rezolute presents RZ358 clinical data-validated model of the pharmacokinetics and glycemic response in congenital hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
May 28, 2020: Rezolute to present clinical data for RZ358, lead candidate in phase 2b trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
Apr 23, 2020: U.S. FDA grants orphan drug designation to AmideBio's glucagon analog for the treatment of congenital hyperinsulinism
Feb 10, 2020: Rezolute initiates Phase 2b clinical trial of lead candidate RZ358 in congenital hyperinsulinism
Jul 29, 2019: Crinetics Pharmaceuticals to receive final award of SBIR grant from NIH for congenital hyperinsulinism
Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on its drug candidate ACTH Antagonist CRN-02481 at ENDO2019
Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism
Apr 09, 2018: Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
Mar 12, 2018: Crinetics Pharmaceuticals Announces Presentation on Hyperinsulinemia Drug Candidate at ENDO 2018
Feb 08, 2018: FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH)
Feb 05, 2018: Hanmi annouces FDA orphan drug designation for LAPSGlucagon Analog
Sep 06, 2017: Crinetics Pharmaceuticals awarded SBIR Grant to develop new therapeutics for congenital hyperinsulinism
Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Hyperinsulinemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hyperinsulinemia - Pipeline by AmideBio LLC, H1 2020
Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Hyperinsulinemia - Pipeline by PegBio Co Ltd, H1 2020
Hyperinsulinemia - Pipeline by Rezolute Inc, H1 2020
Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, H1 2020
Hyperinsulinemia - Pipeline by Sosei Heptares, H1 2020
Hyperinsulinemia - Pipeline by XERIS Pharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Zealand Pharma AS, H1 2020
Hyperinsulinemia - Dormant Projects, H1 2020
Number of Products under Development for Hyperinsulinemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hyperinsulinemia - Pipeline by AmideBio LLC, H1 2020
Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Hyperinsulinemia - Pipeline by PegBio Co Ltd, H1 2020
Hyperinsulinemia - Pipeline by Rezolute Inc, H1 2020
Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, H1 2020
Hyperinsulinemia - Pipeline by Sosei Heptares, H1 2020
Hyperinsulinemia - Pipeline by XERIS Pharmaceuticals Inc, H1 2020
Hyperinsulinemia - Pipeline by Zealand Pharma AS, H1 2020
Hyperinsulinemia - Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development for Hyperinsulinemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
AmideBio LLC
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
PegBio Co Ltd
Rezolute Inc
Seneb BioSciences Inc
Sosei Heptares
XERIS Pharmaceuticals Inc
Zealand Pharma AS
Number of Products under Development for Hyperinsulinemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
AmideBio LLC
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
PegBio Co Ltd
Rezolute Inc
Seneb BioSciences Inc
Sosei Heptares
XERIS Pharmaceuticals Inc
Zealand Pharma AS
